Lumos Pharma, Inc. (LUMO) financial statements (2022 and earlier)
Company profile
Business Address |
4200 MARATHON BLVD. AUSTIN, TX 78756 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 94,809 | 98,679 | 90,549 | 120,738 | 158,708 | 131,490 | 195,620 | ||
Cash and cash equivalents | 94,809 | 98,679 | 90,549 | 120,738 | 158,708 | 131,490 | 195,620 | ||
Receivables | 128 | 26,264 | 824 | 798 | 10,532 | 5,975 | |||
Prepaid expense | 5,921 | 4,954 | |||||||
Other undisclosed current assets | 4,740 | 3,506 | 3,046 | 5,536 | 6,226 | 24,526 | 7,568 | ||
Total current assets: | 99,677 | 128,449 | 94,419 | 127,072 | 175,466 | 167,912 | 208,142 | ||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 735 | ✕ | ✕ | ✕ | ✕ | ||||
Nontrade receivables | 140 | 140 | |||||||
Property, plant and equipment | 79 | 335 | 1,633 | 3,727 | 5,091 | 6,835 | 10,400 | ||
Other undisclosed noncurrent assets | 556 | 249 | |||||||
Total noncurrent assets: | 635 | 584 | 2,368 | 3,867 | 5,231 | 6,835 | 10,400 | ||
TOTAL ASSETS: | 100,312 | 129,033 | 96,787 | 130,939 | 180,697 | 174,747 | 218,542 | ||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 4,778 | 6,142 | 10,684 | 8,694 | 21,723 | 37,192 | 13,281 | ||
Accounts payable | 612 | 244 | 475 | 555 | 9,256 | 22,883 | 3,661 | ||
Accrued liabilities | 4,166 | 5,898 | 10,198 | 8,139 | 12,467 | 14,309 | 8,761 | ||
Taxes payable | 11 | 859 | |||||||
Debt | 43 | 61 | 160 | 232 | 571 | ||||
Deferred rent credit | 92 | ✕ | ✕ | ✕ | |||||
Liability for uncertainty in income taxes | 653 | ||||||||
Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 148 | 481 | 988 | ||
Other undisclosed current liabilities | 352 | 319 | 447 | ||||||
Total current liabilities: | 5,130 | 6,461 | 11,827 | 8,847 | 22,031 | 37,905 | 14,840 | ||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation, including: | 205 | 82 | 43 | 111 | 285 | 368 | |||
Operating lease, liability | 205 | 82 | ✕ | ✕ | ✕ | ✕ | |||
Other undisclosed long-term debt and lease obligation | 43 | 111 | 285 | 368 | |||||
Liabilities, other than long-term debt | 906 | 998 | 1,091 | 1,560 | |||||
Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 998 | 1,091 | 1,560 | ||
Deferred rent credit | 906 | ✕ | ✕ | ✕ | |||||
Other undisclosed noncurrent liabilities | 5,795 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | ||
Total noncurrent liabilities: | 6,205 | 6,000 | 6,082 | 6,949 | 7,109 | 7,376 | 7,928 | ||
Total liabilities: | 11,335 | 12,461 | 17,909 | 15,796 | 29,140 | 45,281 | 22,768 | ||
Stockholders' equity | |||||||||
Stockholders' equity attributable to parent, including: | 88,977 | 116,572 | 78,878 | 115,143 | 151,557 | 129,174 | 195,486 | ||
Treasury stock, value | (114) | (1,454) | (1,417) | (1,142) | (853) | (771) | |||
Additional paid in capital | 185,429 | 182,480 | 413,959 | 407,199 | 389,786 | 295,535 | 276,610 | ||
Accumulated deficit | (96,421) | (65,991) | (334,001) | (291,012) | (237,459) | (165,508) | (80,353) | ||
Other undisclosed stockholders' equity attributable to parent | 83 | 83 | 374 | 373 | 372 | ||||
Other undisclosed stockholders' equity | 292 | 288 | |||||||
Total stockholders' equity: | 88,977 | 116,572 | 78,878 | 115,143 | 151,557 | 129,466 | 195,774 | ||
TOTAL LIABILITIES AND EQUITY: | 100,312 | 129,033 | 96,787 | 130,939 | 180,697 | 174,747 | 218,542 |
Income statement (P&L) ($ in thousands)
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 230 | 168 | 936 | 12,474 | 28,700 | 35,768 | 68,501 | |
Revenue, net | ✕ | ✕ | ✕ | ✕ | 28,711 | 35,768 | 68,501 | |
Gross profit: | 230 | 168 | 936 | 12,474 | 28,700 | 35,768 | 68,501 | |
Operating expenses | (31,577) | (26,471) | (46,070) | (74,912) | (101,592) | (126,526) | (102,103) | |
Other undisclosed operating income | 11 | |||||||
Operating loss: | (31,347) | (26,303) | (45,134) | (62,438) | (72,881) | (90,758) | (33,602) | |
Nonoperating income (expense) | 281 | 6,667 | 2,157 | 1,875 | 371 | 247 | (41) | |
Investment income, nonoperating | 12 | 200 | 2,226 | 2,029 | 616 | |||
Other nonoperating income (expense) | 269 | 6,467 | (19) | (102) | (126) | 247 | (41) | |
Interest and debt expense | (50) | (52) | (119) | 397 | (105) | |||
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (397) | 105 | ||||||
Loss from continuing operations before equity method investments, income taxes: | (31,066) | (19,636) | (43,027) | (60,615) | (72,629) | (90,511) | (33,643) | |
Other undisclosed income from continuing operations before income taxes | 50 | 52 | 119 | |||||
Loss from continuing operations before income taxes: | (31,066) | (19,636) | (42,977) | (60,563) | (72,510) | (90,511) | (33,643) | |
Income tax expense (benefit) | 636 | 13,973 | (12) | 6,968 | 559 | 5,356 | (6,738) | |
Net loss attributable to parent: | (30,430) | (5,663) | (42,989) | (53,595) | (71,951) | (85,155) | (40,381) | |
Preferred stock dividends and other adjustments | (651) | |||||||
Net loss available to common stockholders, diluted: | (30,430) | (6,314) | (42,989) | (53,595) | (71,951) | (85,155) | (40,381) |
Comprehensive Income ($ in thousands)
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (30,430) | (5,663) | (42,989) | (53,595) | (71,951) | (85,155) | (40,381) | |
Comprehensive loss, net of tax, attributable to parent: | (30,430) | (5,663) | (42,989) | (53,595) | (71,951) | (85,155) | (40,381) |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.